X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DIVIS LABORATORIES - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DIVIS LABORATORIES SANOFI INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 36.9 32.8 112.4% View Chart
P/BV x 7.4 5.3 139.1% View Chart
Dividend Yield % 1.2 0.9 130.9%  

Financials

 SANOFI INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DIVIS LABORATORIES
Mar-17
SANOFI INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4,5601,222 373.2%   
Low Rs4,400784 561.2%   
Sales per share (Unadj.) Rs1,028.5153.1 671.8%  
Earnings per share (Unadj.) Rs129.039.9 322.8%  
Cash flow per share (Unadj.) Rs186.044.6 417.1%  
Dividends per share (Unadj.) Rs68.0010.00 680.0%  
Dividend yield (eoy) %1.51.0 152.2%  
Book value per share (Unadj.) Rs753.6201.8 373.4%  
Shares outstanding (eoy) m23.03265.47 8.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.6 66.5%   
Avg P/E ratio x34.725.1 138.3%  
P/CF ratio (eoy) x24.122.5 107.1%  
Price / Book Value ratio x5.95.0 119.6%  
Dividend payout %52.725.0 210.6%   
Avg Mkt Cap Rs m103,174266,266 38.7%   
No. of employees `0003.69.7 37.2%   
Total wages/salary Rs m3,5924,687 76.6%   
Avg. sales/employee Rs Th6,537.74,175.0 156.6%   
Avg. wages/employee Rs Th991.4481.5 205.9%   
Avg. net profit/employee Rs Th819.81,089.3 75.3%   
INCOME DATA
Net Sales Rs m23,68640,643 58.3%  
Other income Rs m708749 94.5%   
Total revenues Rs m24,39441,392 58.9%   
Gross profit Rs m5,28114,460 36.5%  
Depreciation Rs m1,3131,233 106.5%   
Interest Rs m1523 66.4%   
Profit before tax Rs m4,66113,953 33.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6913,349 50.5%   
Profit after tax Rs m2,97010,604 28.0%  
Gross profit margin %22.335.6 62.7%  
Effective tax rate %36.324.0 151.1%   
Net profit margin %12.526.1 48.1%  
BALANCE SHEET DATA
Current assets Rs m15,67340,105 39.1%   
Current liabilities Rs m6,6786,595 101.3%   
Net working cap to sales %38.082.5 46.1%  
Current ratio x2.36.1 38.6%  
Inventory Days Days76119 64.1%  
Debtors Days Days2281 27.7%  
Net fixed assets Rs m8,09819,995 40.5%   
Share capital Rs m230531 43.4%   
"Free" reserves Rs m17,08853,043 32.2%   
Net worth Rs m17,35653,574 32.4%   
Long term debt Rs m00-   
Total assets Rs m25,40061,585 41.2%  
Interest coverage x311.7618.4 50.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.7 141.3%   
Return on assets %11.817.3 68.1%  
Return on equity %17.119.8 86.5%  
Return on capital %26.926.1 103.3%  
Exports to sales %24.50-   
Imports to sales %28.025.2 110.8%   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,62710,259 64.6%   
Fx inflow Rs m7,14535,384 20.2%   
Fx outflow Rs m6,84610,399 65.8%   
Net fx Rs m29924,985 1.2%   
CASH FLOW
From Operations Rs m3,22611,493 28.1%  
From Investments Rs m-1,555-11,372 13.7%  
From Financial Activity Rs m-1,818-93 1,952.7%  
Net Cashflow Rs m-14728 -517.6%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 11.8 122.0%  
FIIs % 14.6 19.0 76.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   15,184 31,796 47.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PFIZER  TORRENT PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare SANOFI INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at All-Time High; Energy & IT Stocks Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 0.3%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jul 18, 2018 10:23 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS